GlassScriptPhysician profile
Parminderpal Singh
NPI 1982899258
$9,054.39
in general payments reported to CMS, 2019-2025
25 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $1,102 · 2021: $869 · 2022: $1,726 · 2023: $804 · 2024: $2,458 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,028 · Travel and Lodging: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,027.73 |
| Travel and Lodging | $670.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,893.17 | 2019-2025 | Clareon, Argos, Acrysof Iq Panoptix Uv Iol |
| Johnson & Johnson Surgical Vision, INC. | $1,369.74 | 2020-2025 | Lipiflow System Activator (Disposable) |
| Lumenis Be INC | $1,117.74 | 2024-2025 | Optilight, M22 |
| Glaukos Corporation | $1,108.91 | 2019-2025 | Idosetr, Idose, Istent Infinite |
| Allergan, INC. | $420.64 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $334.44 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $267.89 | 2022-2024 | Envista Mx60 Iol, Xiidra, Miebo |
| Kala Pharmaceuticals, INC. | $197.61 | 2019-2021 | |
| Boston Scientific Corporation | $169.69 | 2020-2025 | Lux-Dx Insertable Cardiac Monitor |
| Abbvie INC. | $161.11 | 2024-2025 | |
| Rxsight INC | $160.80 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
| Amgen INC. | $137.39 | 2025 | Tepezza |
| Tesaro, INC. | $124.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.35 | 2025 | |
| Mallinckrodt Hospital Products INC. | $86.49 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $86.32 | 2019-2020 | |
| Ivantis, INC | $70.36 | 2020-2021 | |
| Cardiva Medical, INC. | $45.80 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Aerie Pharmaceuticals, INC. | $42.34 | 2019 | |
| Oyster Point Pharma, INC. | $28.57 | 2022 | |
| Dompe US, INC. | $25.11 | 2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $24.03 | 2021 | |
| Medtronic Vascular, INC. | $23.04 | 2019 | |
| Thea Pharma INC. | $18.97 | 2023 | |
| Eyepoint US, INC. | $18.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parminderpal Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.